StockNews.com Initiates Coverage on Kamada (NASDAQ:KMDA)

StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA – Get Rating) in a report issued on Thursday. The firm issued a buy rating on the biotechnology company’s stock.

Kamada Trading Down 3.4 %

KMDA traded down $0.15 on Thursday, hitting $4.23. The company had a trading volume of 36,263 shares, compared to its average volume of 21,945. The company has a market cap of $189.59 million, a PE ratio of -84.58 and a beta of 1.00. Kamada has a 12-month low of $3.72 and a 12-month high of $5.94. The company has a quick ratio of 0.90, a current ratio of 1.84 and a debt-to-equity ratio of 0.07. The business’s fifty day simple moving average is $4.52 and its 200 day simple moving average is $4.49.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Susquehanna International Group LLP purchased a new position in shares of Kamada during the fourth quarter valued at approximately $41,000. Group One Trading L.P. boosted its position in shares of Kamada by 103.7% during the first quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 307,831 shares during the period. Y.D. More Investments Ltd purchased a new position in shares of Kamada during the fourth quarter valued at approximately $91,000. Calton & Associates Inc. boosted its position in shares of Kamada by 37.5% during the fourth quarter. Calton & Associates Inc. now owns 24,255 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 6,616 shares during the period. Finally, Metis Global Partners LLC boosted its position in shares of Kamada by 19.2% during the fourth quarter. Metis Global Partners LLC now owns 33,001 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 5,323 shares during the period. Hedge funds and other institutional investors own 15.29% of the company’s stock.

Kamada Company Profile

(Get Rating)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.